Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biogen Braces For Cost Cuts As Business Transition Continues

25 Jul 2023

• By Jessica Merrill

Biogen is making spending cuts that will impact jobs • Source: Shutterstock

Related Content

Lilly’s Donanemab, Now At FDA, Poised To Join Alzheimer’s Armamentarium

17 Jul 2023

Biogen’s Pipeline: Alzheimer’s Is In, Stroke Is Out

25 Apr 2023

Biogen Halves Aduhelm Price, Readies $500m In Cost Cuts

20 Dec 2021

Leqembi Treatment Infrastructure: If Medicare Pays For It, They Will Come

08 Jul 2023

Eisai/Biogen’s Leqembi Will See Broadened Access To Majority Of Patients

07 Jul 2023

Related Companies

Biogen, Inc.

Sage Therapeutics, Inc.

Eli Lilly and Company

Additional Topics

Sales & Earnings Restructuring Leadership Business Strategies

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.